فينيتوين
مراجع

↑  Simon Maskell; Munir Pirmohamed (4 Mar 2022). "A reference set of clinically relevant adverse drug-drug interactions". Scientific Data (بالإنجليزية). 9 (1). DOI:10.1038/S41597-022-01159-Y. ISSN:2052-4463. QID:Q123478206.
↑  Drug Indications Extracted from FAERS، DOI:10.5281/ZENODO.1435999، QID:Q56863002
↑  Jean-Claude Bradley; Antony John Williams; Andrew S.I.D. Lang (2014). "Jean-Claude Bradley Open Melting Point Dataset". Figshare (بالإنجليزية). DOI:10.6084/M9.FIGSHARE.1031637.V2. QID:Q69644056.
↑  Biltz H (1908). "Über die Konstitution der Einwirkungsprodukte von substituierten Harnstoffen auf Benzil und über einige neue Methoden zur Darstellung der 5,5-Diphenyl-hydantoine" [Constitution of the Products of the Interaction of Substituted Carbamides on Benzil and Certain New Methods for the Preparation of 5,5-Diphenylhydantoin]. Chemische Berichte (بالألمانية). 41 (1): 1379–1393. DOI:10.1002/cber.190804101255.
1 2  Balaji S (2004). "Medical Therapy for Sudden Death". Pediatric Clinics of North America. ج. 51 ع. 5: 1379–1387. DOI:10.1016/j.pcl.2004.04.002. PMID:15331289.
↑  Rogawski MA, Löscher W (Jul 2004). "The 1. neurobiology of antiepileptic drugs". Nat Rev Neurosci 5 (7): 553–564. doi:10.1038/nrn1430. ببمد: 15208697.
↑  American Society of Health-System Pharmacists: 2117–2120. McEvoy, GK (2004). "AHFS drug information 2004".
↑  "WHO Model List of Essential Medicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
↑  2014. "Phenytoin". Lexi-Comp Online. Retrieved 18 April
↑  pg:129 By R S Satoskar Pharmacology and pharmacotheraputics 22ed edition
↑  Shaw, J; Hughes, CM; Lagan, KM; Bell, PM (Nov 2007). "The clinical effect of topical phenytoin on wound healing: a 1. doi:10.1111/j.1365-2133.2007.08160.x. ببمد: 17854378. systematic review.". The British journal of dermatology 157 (5): 997–1004.
↑  for wound healing.". Dermatology online journal 10 (1): 5. 1. ببمد: 15347487. Bhatia, A; Prakash, S (Jul 15, 2004). "Topical phenytoin
↑  Sudan Medical Monitor 10: 63–67 2015). "Topical Phenytoin for Managing Various Ulcers:A meta-analysis.". Thangaraju, Pugazhenthan; Tamilselvan, T; Venkatesan, S; Eswaran, T; singh, H; Giri, VC; showkath Ali, MK (Jul 16
↑  Phenytoin [package insert]. New York, NY: Pfizer Inc.; 2013. Accessed November 2, 2014.
↑  "FDA drug label" (PDF). FDA. Retrieved 18 April 2014.
↑  "Dilantin Toxicity"
↑  Retrieved 20 April 2014. European Journal of Epilepsy 12 (5): 312–315. doi:10.1016/s1059-1311(02)00267-4. ببمد: 12810345 De Marco, Felipe A et al. (July 2003). "Cerebellar Volume and Long-Term Use of Phenytoin"
↑  ببمد: 1547769 interactions: differing effects of the sodium salt and the free acid of phenytoin". Epilepsia 33 (2): 372–375. doi:10.1111/j.1528-1157.1992.tb02330.x Carl GF, Smith ML (1992). "Phenytoin-folate
↑  Aplastic anaemia نسخة محفوظة 19 سبتمبر 2015 على موقع واي باك مشين.
↑  (4th ed.). Baltimore: Lippincott Williams & Wilkins. Beckmann CR et al. (2002). Obstetrics and Gynecology
↑  CDC. (2004). Fetal Alcohol Syndrome: Guidelines for http://www.cdc.gov/fas/faspub.htm Referral and Diagnosis. Can be downloaded at نسخة محفوظة 5 مايو 2007 على موقع واي باك مشين.
↑  Adab N, Tudur SC, Vinten J, Williamson P ببمد: 15266543 in Pregnancy in Women with Epilepsy". Cochrane Database of Systematic Reviews 2004 (3): CD004848. doi:10.1002/14651858.CD004848. Winterbottom J (2004). Adab, Naghme, ed. "Common Antiepileptic Drugs
↑  104914, 2004) p III-216 1.. Report on Carcinogens, Eleventh Edition (PB2005
↑  Maeda T, Sano N, Togei K, Shibata M, Izumi K, Otsuka H (1988). "Lack of carcinogenicity of phenytoin in (C57BL/6 x C3H)F1 mice". Journal of Toxicology and 1. doi:10.1080/15287398809531144. ببمد: 3373561. Environmental Health 24 (1): 111–119.
↑  Arya R, Gulati S, Kabra M, Sahu JK, Kalra V (2011). doi:10.1212/WNL.0b013e3182152844. PMC 3090066. ببمد: 21482950 "Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children". Neurology 76 (15): 1338–1343.
↑  Man CB, Kwan P, Baum L et al. (2007). "Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese". Epilepsia 48 (5): 1015–1018. doi:10.1111/j.1528-1167.2007.01022.x. ببمد: 17509004.
↑  23. ^ "DILANTIN- phenytoin sodium capsule, extended release". http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8848de76-8d74-4620-bcc7-a86a596e5dd9 نسخة محفوظة 2016-03-06 على موقع واي باك مشين.
↑  Caudle, KE; Rettie, AE; Whirl-Carrillo, M; Smith, LH 1. therapeutics 96 (5): 542–8. doi:10.1038/clpt.2014.159. ببمد: 25099164. pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.". Clinical pharmacology and Mintzer, S; Lee, MT; Klein, TE; Callaghan, JT (November 2014). "Clinical
↑  Online Journal 9 (3): 6. ببمد: 12952753. Dermatology Scheinfeld N (2003). "Phenytoin in Cutaneous Medicine: Its Uses, Mechanisms and Side Effects"
↑  Retrieved 20 April 2014 Cuttle, L et al. (August 2000). Metabolism and Disposition 28 (8): 945–950. ببمد: 10901705. "Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation". Drug
↑  "Lexi-Comp Online Interaction Lookup". Lexi-Comp
↑  lippincots modern pharmacology with clinical 1. applications pg no:377 5th Edition
↑  1. from https://www.mims.com/Hongkong/drug/info/Dilantin/?type=full#Actions Dilantin. (2015). In MIMS. Retrieved نسخة محفوظة 10 أغسطس 2014 على موقع واي باك مشين.
↑  Clinical Pharmacology & Therapeutics 66, 563- 568 (December 1999) | doi:10.1053/cp.1999.v66.103277001 Article Tools Send to a friend Export citation Rights and permissions Order commercial reprints Bookmark in Connotea Search Pubmed for Stephen Donahue David A. Flockhart Darrell R. Abernethy Ticlopidine inhibits phenytoin clearance*Ticlopidine inhibits phenytoin clearance *Supported in part by grants AG-08226-07 and GM-08386-08 from the National Institutes of Health, Bethesda, Md.
↑  Introduction to Epilepsy edited by Gonzalo Alarcón نسخة محفوظة 25 سبتمبر 2020 على موقع واي باك مشين.
↑  Chapter 67 - Antiepileptic drug pharmacokinetics and therapeutic drug monitoring pp. 358-366 By Philip N. Patsalos View chapter as PDF Antiepileptic drug pharmacokinetics and therapeutic drug monitoring By Philip N. Patsalos
↑  "PNYFR - Clinical: Phenytoin, Total and Free, Serum". مؤرشف من الأصل في 2015-05-26.
↑  Biltz H (1908). "Über die Konstitution der Einwirkungsprodukte von substituierten Harnstoffen auf Benzil und über einige neue Methoden zur Darstellung der 5,5-Diphenyl-hydantoine" [Constitution of the Products of the Interaction of Substituted Carbamides on Benzil and Certain New Methods for the Preparation of 5,5-Diphenylhydantoin]. Chemische Berichte (in German) 41 (1): 1379–1393. doi:10.1002/cber.190804101255.
↑  Retrieved 20 April 2014. Carter, BL et al. (1981). doi:10.1097/00007691-198104000-00003. ببمد: 7336470 "Effect of antacids on phenytoin availability". Therapeutic Drug Monitoring 3 (4): 333–340.
↑  "AERS data". FDA. Retrieved 18 April 2014
↑  Phenytoin Sodium Flynn Hard Capsules...Marketing authorisation holder, Flynn Pharma patient information leaflet at the electronic Medicines Compendium, 24 April 2014.Accessed 13 May 2014.
↑  FDA warns of risks from epilepsy drugs. نسخة محفوظة 8 أبريل 2020 على موقع واي باك مشين.
↑  Healthcare Professionals Advised That Epanutin Capsules Are Only To Be Available Under The Generic Name, MediGuard, Durham, NC, 2 October 2012.Accessed 13 May 2014.
↑  Pharma firm hikes cost of epilepsy drug 24 times, Stephen Adams, Medical Correspondent, Daily Telegraph, London, 12 October 2012.Accessed 13 May 2014.
↑  Price of anti-epilepsy drug rockets, Mark Gould, Pulse, London, 21 November 2012.Accessed 13 May 2014.
↑  essential pharmacology by KD Tripathi 6E pg:405